Annexon, Inc.

NASDAQ:ANNX

Biotechnology

Healthcare
$3.52 -0.71%

-$0.04 today

Market cap
$576.73M
Beta
1.18
P/E (TTM)
-4.8
EPS (TTM)
-$1.01
52W Low $1.85High $7.18

Volume 2.98M

Average 2.56M

ANNX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Annexon, Inc.NASDAQ: ANNX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $957K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $1.9M.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $957K or moves back toward the trailing-twelve-month quarterly average of $475.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$957K+1.3% QoQ
Last fiscal yearDec 2025
$3.69M+6.7% YoY
LTMMar 2026
$1.9M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+6.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
3.69M USD
Year-over-year change
+6.7%

Cost of Revenue vs competitors

How ANNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
ANNX Competitors
Cost of Revenue for ANNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$59.51M USD-6.4%-62.5%56.7%
PRTAProthena Corporation plcLTM Mar 2026$30.8M USD——53.2%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M USD-86.0%-44.1%23.7%
ANNXAnnexon, Inc.LTM Mar 2026$1.9M USD———
ALMSAlumis Inc. Common StockLTM Jun 2026$871K USD+6.2%+140.9%11.8%
QTTBQ32 Bio Inc.LTM Mar 2026$362K USD+0.6%-46.8%0.7%
ABVXAbivax S.A.FY2025€0 EUR———
IMVTImmunovant, Inc.LTM Sep 2026$0 USD——0.0%
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
ANABAnaptysBio, Inc.LTM Mar 2026-$38.15M USD-122.7%-69.9%16.4%
Peer median (excluding ANNX) —-2.9%-46.8%16.4%

Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0003.45M3.69M
Gross Profit000(3.45M)(3.69M)
Gross Margin—————
Research & Development100.07M112.5M113.76M119.45M184.7M
Selling, General & Admin30.65M30.95M28.02M34.63M31.71M
Operating Expenses130.71M145.6M143.72M150.62M212.72M
Depreciation & Amortization2.14M2.15M2.15M3.45M2.65M
EBITDA(128.18M)(139.8M)(132.09M)(134.75M)(204.04M)
EBITDA Margin—————
Operating Income(130.71M)(145.6M)(143.72M)(154.07M)(216.41M)
Operating Margin—————
Interest Income390K3.65M9.49M15.87M9.72M
Interest Expense00000
Other Income / Expenses390K3.65M9.49M15.87M9.72M
Income Before Tax(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Net Margin—————
EPS (Basic)(3.34)(2.60)(1.77)(1.01)(1.34)
EPS (Diluted)(3.34)(2.60)(1.77)(1.01)(1.34)
Weighted Avg Shares38.32M54.67M75.67M137.4M155.11M
Weighted Avg Shares (Diluted)38.32M54.67M75.67M137.4M155.11M

Annexon, Inc.

NASDAQ:ANNX

Intrinsic Alpha fair value

Locked

Current Price

$3.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.